# OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer

> **NCT05935774** · PHASE2 · WITHDRAWN · sponsor: **University of Washington**

## Conditions studied

- Metastatic Lung Non-Small Cell Carcinoma
- Recurrent Lung Non-Small Cell Carcinoma
- Stage IV Lung Cancer AJCC v8

## Interventions

- **BIOLOGICAL:** Atezolizumab
- **PROCEDURE:** Biopsy
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **OTHER:** Electronic Health Record Review
- **PROCEDURE:** Magnetic Resonance Imaging
- **DRUG:** Trabedersen (OT-101)

## Key facts

- **NCT ID:** NCT05935774
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-12-01
- **Primary completion:** 2028-07-31
- **Final completion:** 2028-07-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Withdrawn prior to opening to accrual.
- **Last updated:** 2023-08-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05935774

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05935774, "OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05935774. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*